PRMT1 and neuroblastoma: Interestingly, these compounds exhibited similar potency in MYCN-amplified versus non-amplified neuroblastoma cell lines, which is consistent with a similar reduction of cell proliferation upon PRMT1 silencing regardless of MYCN amplification (Fig. 2 and Supplementary Figure S2).